Search

Search Constraints

You searched for: Author/Creator Devauchelle-Pensec, Valerie

Search Results

1. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. (19th September 2020)

2. AB0187 CAN ARTIFICIAL INTELLIGENCE REPLACE MANUAL SEARCH FOR SYSTEMATIC LITERATURE REVIEW ON CUTANEOUS MANIFESTATIONS IN PRIMARY SJOGREN'S SYNDROME?. (June 2019)

3. AB0394 SERUM CALPROTECTIN AS A PREDICTIVE MARKER OF THERAPEUTIC RESPONSE TO ADALIMUMAB IN RHEUMATOID ARTHRITIS. (June 2019)

4. AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS). (June 2019)

5. AB0550 PHENOTYPE OF BIOPSY-PROVEN PATIENTS WITH PRIMARY SJÖGREN SYNDROME LACKING RO AUTOANTIBODIES: HIGH FREQUENCY OF DRYNESS SYMPTOMS WITH LOW SYSTEMIC ACTIVITY (BIG DATA SJÖGREN PROJECT). (June 2019)

6. AB0708 INFLUENCE OF IMMUNOGENICITY ON LONG-TERM MAINTENANCE OF ADALIMUMAB IN SPONDYLOARTHRITIS. (June 2019)

7. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. (6th April 2022)

8. Epidemiological profile and north–south gradient driving baseline systemic involvement of primary Sjögren's syndrome. (24th December 2019)

9. FRI0100 TOWARDS THE LOWEST EFFICACIOUS DOSE (TOLEDO): RESULTS OF A MULTICENTER NON-INFERIORITY RANDOMIZED OPEN-LABEL CONTROLLED TRIAL ASSESSING TOCILIZUMAB OR ABATACEPT INJECTION SPACING IN RHEUMATOID ARTHRITIS PATIENTS IN REMISSION. (June 2019)